Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24:182–96.

Article  PubMed  PubMed Central  Google Scholar 

Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238–46.

Article  PubMed  PubMed Central  Google Scholar 

Arora P, Gupta A, Golzy M, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 2016;17:1–8.

Article  Google Scholar 

Klatte DCF, Gasparini A, Xu H, et al. Association between proton pump inhibitor use and risk. Gastroenterology. 2017;153:702–10.

Article  PubMed  CAS  Google Scholar 

Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682–91.

Article  PubMed  CAS  Google Scholar 

Dutta AK, Jain A, Jearth V, et al. Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship. Indian J Gastroenterol. 2023;42:601–28.

Article  PubMed  Google Scholar 

Blass KG, Thibert RJ, Lam LK. A study of the mechanism of the Jaffé reaction. Z Klin Chem Klin Biochem. 1974;12:336–43.

PubMed  CAS  Google Scholar 

Van den Brand JAJG, van Boekel GAJ, Willems HL, Kiemeney LALM, den Heijer M, Wetzels JFM. Introduction of the CKD-EPI equation to estimate glomerular filtration rate in a Caucasian population. Nephrol Dialysis Transplant. 2011;26:3176–81.

Article  Google Scholar 

Chapter 1: Definition and classification of CKD. Kidney Int. Suppl (2011). 2013;3:19–62.

Kidney Disease: Improving Global Outcomes (KDIGO). Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2012;2:1138.

Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91:1482–94.

Article  PubMed  CAS  Google Scholar 

Leonard CE, Freeman CP, Newcomb CW, et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. 2012;21:1155–72.

Article  PubMed  CAS  Google Scholar 

Yang H, Juang SY, Liao KF. Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Res Clin Pract. 2019;147:67–75.

Article  PubMed  CAS  Google Scholar 

Wu B, Shang W, Li Y, et al. Association between proton pump inhibitors use and kidney diseases: a meta-analysis. Int J Clin Exp Med. 2018;11:6465–73.

Google Scholar 

Hussain S, Singh A, Habib A, Najmi AK. Proton pump inhibitors use and risk of chronic kidney disease: evidence-based meta-analysis of observational studies. Clin Epidemiol Global Health. 2019;7:46–52.

Article  Google Scholar 

Rodríguez-Poncelas A, Barceló MA, Saez M, Coll-de-Tuero G. Duration and dosing of proton pump inhibitors associated with high incidence of chronic kidney disease in population-based cohort. PLoS ONE. 2018;13:1–16.

Article  Google Scholar 

Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy. 2019;39:443–53.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ma C, Shaheen AA, Congly SE, Andrews CN, Moayyedi P, Forbes N. Interpreting reported risks associated with use of proton pump inhibitors: residual confounding in a 10-year analysis of national ambulatory data. Gastroenterology. 2020;158:780–2.

Article  PubMed  Google Scholar 

Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol. 2012;9:132–9.

Article  PubMed  CAS  Google Scholar 

Grimes DA, Schulz KF. False alarms and pseudo-epidemics: the limitations of observational epidemiology. Obstet Gynecol. 2012;120:920–7.

Article  PubMed  Google Scholar 

Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27:3153–63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kazancioǧlu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl. 2013;3:368–71.

Article  Google Scholar 

Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep. 2017;5:127–37.

Article  Google Scholar 

Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med. 2013;11:95.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu X, Zhang W, Ren H, Chen X, Xie J, Chen N. Diuretics-associated acute kidney injury: clinical and pathological analysis. Ren Fail. 2014;36:1051–5.

Article  PubMed  CAS  Google Scholar 

Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457–68.

PubMed  PubMed Central  Google Scholar 

Oikonomou KA, Kapsoritakis AN, Stefanidis I, Potamianos SP. Drug-induced nephrotoxicity in inflammatory bowel disease. Nephron Clin Pract. 2011;119:c89–96.

Article  PubMed  CAS  Google Scholar 

Mehmet NM. Effect of urinary stone disease and its treatment on renal function. World J Nephrol. 2015;4:271.

Article  PubMed Central  Google Scholar